AbbVie Inc (ABBV.N)
BRIEF-AbbVie announces positive topline results from phase 3 trial evaluating Venclexta/Venclyxto tablets in combination with Rituxan
* AbbVie announces positive topline results from phase 3 trial evaluating Venclexta™/Venclyxto™ (Venetoclax) tablets in combination with Rituxan® (Rituximab) for the treatment of patients with relapsed/refractory chronic lymphocytic Leukemia
* adds to aa, british land, ip group , lloyds-monthly update Further company coverage:
AbbVie Inc said on Monday two patients died in a late-stage trial of its rheumatoid arthritis drug but that the deaths were not linked to the drug, which met the study's main goals.
Sept 11 AbbVie Inc said on Monday two patients died in a late-stage trial of its rheumatoid arthritis drug but that the deaths were not linked to the drug, which met the study's main goals.
Sept 11 AbbVie Inc said on Monday two patients died in a late-stage trial testing its drug to treat patients with moderate to severe rheumatoid arthritis.
* AbbVie's upadacitinib (ABT-494) meets all primary and ranked secondary endpoints in second phase 3 study in rheumatoid arthritis
* Says board of directors of Abbvie Inc declared a quarterly cash dividend of $0.64 per share
* Dow down 0.1 pct, S&P down 0.02 pct, Nasdaq up 0.07 pct (Updates to close of U.S. market)
* Coherus Biosciences provides update on ‘619 IPR institution decision
AbbVie Inc said on Thursday its experimental drug to treat adults with moderate-to-severe eczema met the main goal in a mid-stage study, dragging down shares of rival U.S. biotech firm Regeneron Pharmaceuticals Inc.
|Johnson & Johnson (JNJ.N)||$131.75||-1.47|
|Pfizer Inc. (PFE.N)||$35.97||-0.02|
|Novartis AG (NOVN.S)||CHF82.95||+0.05|
|Merck & Co., Inc. (MRK.N)||$65.60||-0.19|
|Roche Holding Ltd. (ROG.S)||CHF249.00||+2.00|
|Roche Holding Ltd. (RO.S)||CHF249.00||+1.40|
|Abbott Laboratories (ABT.N)||$51.43||-0.46|
|Eli Lilly and Co (LLY.N)||$83.33||+1.31|
|Sanofi SA (SASY.PA)||€83.87||--|